# Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma

> **NCT00003741** · PHASE1 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** monoclonal antibody HeFi-1

## Key facts

- **NCT ID:** NCT00003741
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-02
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003741, "Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*